Immunovant (IMVT) statistics

Analysts' price targets and ratings, ownership, short interest, trading figures and dates for Immunovant, as the data feed reports them.

Analysts' mean target, 16 analysts
$48.63
45.9% above the price

The 16 analysts reported by the data feed have a mean price target for Immunovant of $48.63, 45.9% above the $33.33 price (range $33.00–$62.00). 19.91% of the float was sold short as of Oct 30, 2026. Institutions hold 52.8% of the shares and insiders 55.9%. Source: Yahoo Finance, read Nov 17, 2026.

Key facts

Analysts' mean target
$48.63+45.9% vs price
Analysts
16
Short interest
19.91%of float, Oct 30, 2026
Short ratio
13.4 days
Institutions
52.8%
Insiders
55.90%
Beta
0.94
Next earnings
Feb 5, 2027estimated

Figures read . Source: Yahoo Finance (quoteSummary: key statistics, financial data, recommendation trend, major holders, insider purchases, calendar events). Analysts' targets and ratings, ownership and short interest are the data feed's figures and can lag the filings and exchange reports they come from. Figures, not advice.

Analysts' consensus as reported by the data feed

16 analysts covering Immunovant, as the data feed counts them. Price targets and ratings are other people's estimates — not facts about the company, and not advice. Distances are from the latest price the feed gave with these figures, $33.33.

Analysts' price targets for Immunovant
Mean price target$48.6345.9% above the price (+45.9%)
Median price target$48.0044.0% above the price (+44.0%)
Highest target$62.0086.0% above the price (+86.0%)
Lowest target$33.001.0% below the price (−1.0%)
Analysts with a target16

Ratings this month · 17 analysts

Strong buy 2(12%)Buy 11(65%)Hold 4(24%)
Analysts' ratings of Immunovant this month, by rating
RatingAnalystsShare
Strong buy212%
Buy1165%
Hold424%
Sell00%
Strong sell00%

The feed averages these to 1.59 on its scale of 1 (strong buy) to 5 (strong sell), which it labels “buy”.

Who owns Immunovant

Ownership of Immunovant
Held by institutions52.8%318 institutions; percent of shares outstanding
Held by institutions, of the float119.7%
Held by insiders55.90%percent of shares outstanding
Shares outstanding206.95M
Float92.16Mshares available to trade
Insiders' net purchases, six months+69.52K11 purchases (423.8K shares), 21 sales (354.28K shares)

Percentages are of shares outstanding unless the row says float. Insiders' net purchases are shares bought minus shares sold by insiders, as the data feed totals their reported trades.

Short interest as reported by the data feed

Shares sold short and not yet covered, as of Oct 30, 2026. Short interest is counted twice a month, so this is not today's figure.

Short interest in Immunovant
Shares short18.55Mas of Oct 30, 2026
Percent of float19.91%shares short ÷ float
Percent of shares outstanding8.97%shares short ÷ shares outstanding
Short ratio (days to cover)13.4shares short ÷ average daily volume

Immunovant short interest from FINRA, with its history

Trading figures

Trading figures for Immunovant
Beta0.94movement against the market; 1 moves with it
52-week high$45.42
52-week low$21.86
Average volume, 3 months1.44Mshares a day
Average volume, 10 days1.66Mshares a day

Dates to know

Upcoming and recent dates for Immunovant
Next earnings reportFeb 5, 2027the feed's estimate, not confirmed

Questions and answers

What is the analysts' price target for Immunovant (IMVT)?

As reported by the data feed, the mean price target of the 16 analysts covering Immunovant is $48.63, 45.9% above the latest price of $33.33. The highest target is $62.00 and the lowest $33.00. Targets are analysts' estimates, not facts about the company and not advice.

How do analysts rate Immunovant stock?

Of the 17 ratings the data feed reports for the current month, 2 are strong buy, 11 buy, 4 hold, 0 sell and 0 strong sell.

How many Immunovant shares are sold short?

As reported by the data feed, 18.55M shares were sold short, 19.91% of the float as of Oct 30, 2026. At the average daily volume that is 13.4 days to cover. Short interest is reported twice a month; it is not today's figure.

Who owns Immunovant stock?

As reported by the data feed, institutions hold 52.8% of the shares (318 institutions) and insiders 55.9%. There are 206.95M shares outstanding, of which 92.16M are in the float.

When is Immunovant's next earnings report?

The data feed lists Feb 5, 2027, marked as its estimate rather than a date the company has confirmed.

How much does Immunovant stock move with the market?

Its beta, as reported by the data feed, is 0.94: a beta above 1 means the share has tended to move more than the market, below 1 less. Over the past 52 weeks it traded between $21.86 and $45.42.

Cite this page

Funkfolio, “Immunovant (IMVT) statistics: analyst targets and short interest”, data as of 17 November 2026. https://funkfolio.com/stock/IMVT/statistics

Underlying data: Yahoo Finance.